PrescrYbe review

PrescrYbe's choices need product-specific clarification. In particular, the oral card appears to lead into an injection product's intake mapping; confirm the route, active ingredient and price before paying.

PrescrYbe's terms describe a technology platform, not a clinic or pharmacy. Independent clinical partners include OpenLoop Health and affiliates; licensed pharmacy partners fill prescriptions. A specific clinician, practice and pharmacy are not assigned on the public pages.

The first public intake asks for contact information and shows no selected-plan price. PrescrYbe describes clinician visits, follow-ups, coaching and shipping, with qualifiers on visits and coaching. A subscription may include labs or other services, but no routine lab requirement or plan-specific testing charge is established. Terms require adulthood and service availability in the patient's state; the footer's 50-state claim is qualified by jurisdiction-specific limits.

GLP-1 cards start at $169 for a microdose injection, $239 for a medical weight-loss injection and $229 for an oral option. The cards do not clearly state the billing period, active ingredient, supply or complete first payment. The terms describe a bundled cash-pay subscription with consultations, prescribed medication and shipping; renewal cadence and cutoff appear at checkout. The refund policy says the first month is paid when intake is completed.

The GLP-1 page says nothing bills automatically and suggests price can depend on insurance status, while the terms describe recurring charges and say services are not billed to insurance. Those statements need reconciliation for the actual plan. The refund policy asks for cancellation at least 72 hours before the next bill, with no ordinary refund of current or prior months. If the provider medically disqualifies a patient at initial enrollment, the policy promises a full refund. If a patient later becomes ineligible, it says the subscription is canceled and a refund may be issued. Confirm how later charges are handled for the selected plan.

The landing page presents injection and single-ingredient oral GLP-1 categories, while the home page mentions semaglutide and tirzepatide. The public cards do not establish which ingredient, oral formulation or dose belongs to each price. The oral card's public intake destination appears to share a product identifier with an injection card, so its selected route needs explicit confirmation. The site says compounded medications are not FDA-approved; eligibility is a clinician decision.